PharmaDrug Inc. CEO Daniel Cohen joined Proactive's Stephen Gunnion with news of interim positive results for the company's preclinical cancer study which evaluated the effectiveness of cepharanthine-2HCl alone, or when used in combination with standard of care (SoC) chemotherapy.
Cohen telling Proactive that IND-enabling animal efficacy studies to support future human clinical studies in oncology will commence in November.